The PI3K Pathway in Human Disease

Cell

Volumn 170, Issue 4, 2017, Pages 605-635

  Fruman, David A ^a   Chiu, Honyin ^a   Hopkins, Benjamin D ^b   Bagrodia, Shubha ^c   Cantley, Lewis C ^b   Abraham, Robert T ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IDELALISIB; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE;

ADAPTIVE IMMUNITY; CELL HETEROGENEITY; CELL METABOLISM; COWDEN SYNDROME; DISEASES; ENZYME ACTIVATION; ENZYME METABOLISM; ENZYME STRUCTURE; HUMAN; IMMUNE DEFICIENCY; INNATE IMMUNITY; LYMPHANGIOLEIOMYOMATOSIS; MALIGNANT NEOPLASM; MOLECULARLY TARGETED THERAPY; MUTATION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TISSUE OVERGROWTH; TREATMENT RESPONSE; TUBEROUS SCLEROSIS; TUMOR MICROENVIRONMENT; ANIMAL; CELL FUNCTION; IMMUNE SYSTEM; METABOLISM; NEOPLASMS; PATHOLOGY;

ANIMALS; CELL PHYSIOLOGICAL PHENOMENA; HUMANS; IMMUNE SYSTEM; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION;

EID: 85027484120     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2017.07.029     Document Type: Review

References (291)

1. Adams, D.M., Trenor, C.C. 3rd, Hammill, A.M., Vinks, A.A., Patel, M.N., Chaudry, G., Wentzel, M.S., Mobberley-Schuman, P.S., Campbell, L.M., Brookbank, C., et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics, 137, 2016, e20153257.
2. Ahmad, S., Abu-Eid, R., Shrimali, R., Webb, M., Verma, V., Doroodchi, A., Berrong, Z., Samara, R., Rodriguez, P.C., Mkrtichyan, M., Khleif, S.N., Differential PI3Kδ signaling in CD4(+) T-cell subsets enables selective targeting of T regulatory cells to enhance cancer immunotherapy. Cancer Res. 77 (2017), 1892–1904.
3. Aksoy, E., Taboubi, S., Torres, D., Delbauve, S., Hachani, A., Whitehead, M.A., Pearce, W.P., Berenjeno, I.M., Nock, G., Filloux, A., et al. The p110δ isoform of the kinase PI(3)K controls the subcellular compartmentalization of TLR4 signaling and protects from endotoxic shock. Nat. Immunol. 13 (2012), 1045–1054.
4. Ali, K., Bilancio, A., Thomas, M., Pearce, W., Gilfillan, A.M., Tkaczyk, C., Kuehn, N., Gray, A., Giddings, J., Peskett, E., et al. Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature 431 (2004), 1007–1011.
5. Ali, K., Soond, D.R., Piñeiro, R., Hagemann, T., Pearce, W., Lim, E.L., Bouabe, H., Scudamore, C.L., Hancox, T., Maecker, H., et al. Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 510 (2014), 407–411.
6. Amin, R.H., Schlissel, M.S., Foxo1 directly regulates the transcription of recombination-activating genes during B cell development. Nat. Immunol. 9 (2008), 613–622.
7. André, F., Hurvitz, S., Fasolo, A., Tseng, L.-M., Jerusalem, G., Wilks, S., O'Regan, R., Isaacs, C., Toi, M., Burris, H., et al. Molecular alterations and everolimus efficacy in human epidermal growth factor receptor 2-overexpressing metastatic breast cancers: Combined exploratory biomarker analysis from BOLERO-1 and BOLERO-3. J. Clin. Oncol. 34 (2016), 2115–2124.
8. Atefi, M., Avramis, E., Lassen, A., Wong, D.J., Robert, L., Foulad, D., Cerniglia, M., Titz, B., Chodon, T., Graeber, T.G., et al. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin. Cancer Res. 20 (2014), 3446–3457.
9. Auger, K.R., Serunian, L.A., Soltoff, S.P., Libby, P., Cantley, L.C., PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells. Cell 57 (1989), 167–175.
10. Backer, J.M., The regulation of class IA PI 3-kinases by inter-subunit interactions. Curr. Top. Microbiol. Immunol. 346 (2010), 87–114.
11. Backer, J.M., The intricate regulation and complex functions of the Class III phosphoinositide 3-kinase Vps34. Biochem. J. 473 (2016), 2251–2271.
12. Bago, R., Sommer, E., Castel, P., Crafter, C., Bailey, F.P., Shpiro, N., Baselga, J., Cross, D., Eyers, P.A., Alessi, D.R., The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth. EMBO J. 35 (2016), 1902–1922.
13. Barr, P.M., Saylors, G.B., Spurgeon, S.E., Cheson, B.D., Greenwald, D.R., O'Brien, S.M., Liem, A.K.D., Mclntyre, R.E., Joshi, A., Abella-Dominicis, E., et al. Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood 127 (2016), 2411–2415.
14. Baselga, J., Campone, M., Piccart, M., Burris, H.A. 3rd, Rugo, H.S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K.I., Lebrun, F., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366 (2012), 520–529.
15. Baselga, J., Im, S.-A., Iwata, H., Cortés, J., De Laurentiis, M., Jiang, Z., Arteaga, C.L., Jonat, W., Clemons, M., Ito, Y., et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 18 (2017), 904–916.
16. Basu, B., Dean, E., Puglisi, M., Greystoke, A., Ong, M., Burke, W., Cavallin, M., Bigley, G., Womack, C., Harrington, E.A., et al. First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014. Clin. Cancer Res. 21 (2015), 3412–3419.
17. Bendell, J.C., Rodon, J., Burris, H.A., de Jonge, M., Verweij, J., Birle, D., Demanse, D., De Buck, S.S., Ru, Q.C., Peters, M., et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 30 (2012), 282–290.
18. Bendell, J.C., Kelley, R.K., Shih, K.C., Grabowsky, J.A., Bergsland, E., Jones, S., Martin, T., Infante, J.R., Mischel, P.S., Matsutani, T., et al. A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. Cancer 121 (2015), 3481–3490.
19. Bendell, J.C., Kurkjian, C., Infante, J.R., Bauer, T.M., Burris, H.A. 3rd, Greco, F.A., Shih, K.C., Thompson, D.S., Lane, C.M., Finney, L.H., Jones, S.F., A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors. Invest. New Drugs 33 (2015), 463–471.
20. Bentley, J., Itchayanan, D., Barnes, K., McIntosh, E., Tang, X., Downes, C.P., Holman, G.D., Whetton, A.D., Owen-Lynch, P.J., Baldwin, S.A., Interleukin-3-mediated cell survival signals include phosphatidylinositol 3-kinase-dependent translocation of the glucose transporter GLUT1 to the cell surface. J. Biol. Chem. 278 (2003), 39337–39348.
21. Bihani, T., Ezell, S.A., Ladd, B., Grosskurth, S.E., Mazzola, A.M., Pietras, M., Reimer, C., Zinda, M., Fawell, S., D'Cruz, C.M., Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers. Oncotarget 6 (2015), 2407–2420.
22. Bissler, J.J., McCormack, F.X., Young, L.R., Elwing, J.M., Chuck, G., Leonard, J.M., Schmithorst, V.J., Laor, T., Brody, A.S., Bean, J., et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 358 (2008), 140–151.
23. Bissler, J.J., Kingswood, J.C., Radzikowska, E., Zonnenberg, B.A., Frost, M., Belousova, E., Sauter, M., Nonomura, N., Brakemeier, S., de Vries, P.J., et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 381 (2013), 817–824.
24. Bohnacker, T., Prota, A.E., Beaufils, F., Burke, J.E., Melone, A., Inglis, A.J., Rageot, D., Sele, A.M., Cmiljanovic, V., Cmiljanovic, N., et al. Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention. Nat. Commun., 8, 2017, 14683.
25. Bojarczuk, K., Sasi, B.K., Gobessi, S., Innocenti, I., Pozzato, G., Laurenti, L., Efremov, D.G., BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199. Blood 127 (2016), 3192–3201.
26. Bosch, A., Li, Z., Bergamaschi, A., Ellis, H., Toska, E., Prat, A., Tao, J.J., Spratt, D.E., Viola-Villegas, N.T., Castel, P., et al. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci. Transl. Med., 7, 2015, 283ra51.
27. Brastianos, P.K., Carter, S.L., Santagata, S., Cahill, D.P., Taylor-Weiner, A., Jones, R.T., Van Allen, E.M., Lawrence, M.S., Horowitz, P.M., Cibulskis, K., et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 5 (2015), 1164–1177.
28. Britschgi, A., Andraos, R., Brinkhaus, H., Klebba, I., Romanet, V., Müller, U., Murakami, M., Radimerski, T., Bentires-Alj, M., JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell 22 (2012), 796–811.
29. Britten, C.D., PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. Cancer Chemother. Pharmacol. 71 (2013), 1395–1409.
30. Brown, K.K., Toker, A., The phosphoinositide 3-kinase pathway and therapy resistance in cancer. F1000Prime Rep., 7, 2015, 13.
31. de Bruin, E.C., McGranahan, N., Mitter, R., Salm, M., Wedge, D.C., Yates, L., Jamal-Hanjani, M., Shafi, S., Murugaesu, N., Rowan, A.J., et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346 (2014), 251–256.
32. Burke, J.E., Williams, R.L., Synergy in activating class I PI3Ks. Trends Biochem. Sci. 40 (2015), 88–100.
33. Burke, J.E., Perisic, O., Masson, G.R., Vadas, O., Williams, R.L., Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA). Proc. Natl. Acad. Sci. USA 109 (2012), 15259–15264.
34. Byrd, J.C., Furman, R.R., Coutre, S.E., Flinn, I.W., Burger, J.A., Blum, K.A., Grant, B., Sharman, J.P., Coleman, M., Wierda, W.G., et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369 (2013), 32–42.
35. Calamito, M., Juntilla, M.M., Thomas, M., Northrup, D.L., Rathmell, J., Birnbaum, M.J., Koretzky, G., Allman, D., Akt1 and Akt2 promote peripheral B-cell maturation and survival. Blood 115 (2010), 4043–4050.
36. Cantley, L.C., Songyang, Z., Specificity in recognition of phosphopeptides by src-homology 2 domains. J. Cell Sci. Suppl. 18 (1994), 121–126.
37. Cardnell, R.J., Feng, Y., Diao, L., Fan, Y.-H., Masrorpour, F., Wang, J., Shen, Y., Mills, G.B., Minna, J.D., Heymach, J.V., Byers, L.A., Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin. Cancer Res. 19 (2013), 6322–6328.
38. Cardnell, R.J., Feng, Y., Mukherjee, S., Diao, L., Tong, P., Stewart, C.A., Masrorpour, F., Fan, Y., Nilsson, M., Shen, Y., et al. Activation of the PI3K/mTOR pathway following PARP inhibition in small cell lung cancer. PLoS ONE, 11, 2016, e0152584.
39. Carlo, M.I., Molina, A.M., Lakhman, Y., Patil, S., Woo, K., DeLuca, J., Lee, C.H., Hsieh, J.J., Feldman, D.R., Motzer, R.J., Voss, M.H., A Phase Ib study of BEZ235, a dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), in patients with advanced renal cell carcinoma. Oncologist 21 (2016), 787–788.
40. Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A.T., Thomas, G., Kozma, S.C., et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 118 (2008), 3065–3074.
41. Castel, P., Ellis, H., Bago, R., Toska, E., Razavi, P., Carmona, F.J., Kannan, S., Verma, C.S., Dickler, M., Chandarlapaty, S., et al. PDK1-SGK1 signaling sustains AKT-independent mTORC1 activation and confers resistance to PI3Kα inhibition. Cancer Cell 30 (2016), 229–242.
42. Chakrabarty, A., Sánchez, V., Kuba, M.G., Rinehart, C., Arteaga, C.L., Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc. Natl. Acad. Sci. USA 109 (2012), 2718–2723.
43. Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P.K., Baselga, J., Rosen, N., AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19 (2011), 58–71.
44. Chang, H.W., Aoki, M., Fruman, D., Auger, K.R., Bellacosa, A., Tsichlis, P.N., Cantley, L.C., Roberts, T.M., Vogt, P.K., Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science 276 (1997), 1848–1850.
45. Chang, J.T., Palanivel, V.R., Kinjyo, I., Schambach, F., Intlekofer, A.M., Banerjee, A., Longworth, S.A., Vinup, K.E., Mrass, P., Oliaro, J., et al. Asymmetric T lymphocyte division in the initiation of adaptive immune responses. Science 315 (2007), 1687–1691.
46. Cheah, C.Y., Nastoupil, L.J., Neelapu, S.S., Forbes, S.G., Oki, Y., Fowler, N.H., Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood 125 (2015), 3357–3359.
47. Chen, J., Limon, J.J., Blanc, C., Peng, S.L., Fruman, D.A., Foxo1 regulates marginal zone B-cell development. Eur. J. Immunol. 40 (2010), 1890–1896.
48. Chi, H., Regulation and function of mTOR signalling in T cell fate decisions. Nat. Rev. Immunol. 12 (2012), 325–338.
49. Cho, S.H., Raybuck, A.L., Stengel, K., Wei, M., Beck, T.C., Volanakis, E., Thomas, J.W., Hiebert, S., Haase, V.H., Boothby, M.R., Germinal centre hypoxia and regulation of antibody qualities by a hypoxia response system. Nature 537 (2016), 234–238.
50. Chudasama, K.K., Winnay, J., Johansson, S., Claudi, T., König, R., Haldorsen, I., Johansson, B., Woo, J.R., Aarskog, D., Sagen, J.V., et al. SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling. Am. J. Hum. Genet. 93 (2013), 150–157.
51. Compagno, M., Wang, Q., Pighi, C., Cheong, T.C., Meng, F.L., Poggio, T., Yeap, L.S., Karaca, E., Blasco, R.B., Langellotto, F., et al. Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells. Nature 542 (2017), 489–493.
52. Condliffe, A.M., Davidson, K., Anderson, K.E., Ellson, C.D., Crabbe, T., Okkenhaug, K., Vanhaesebroeck, B., Turner, M., Webb, L., Wymann, M.P., et al. Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 106 (2005), 1432–1440.
53. Conley, M.E., Dobbs, A.K., Quintana, A.M., Bosompem, A., Wang, Y.-D., Coustan-Smith, E., Smith, A.M., Perez, E.E., Murray, P.J., Agammaglobulinemia and absent B lineage cells in a patient lacking the p85α subunit of PI3K. J. Exp. Med. 209 (2012), 463–470.
54. Corcoran, R.B., Rothenberg, S.M., Hata, A.N., Faber, A.C., Piris, A., Nazarian, R.M., Brown, R.D., Godfrey, J.T., Winokur, D., Walsh, J., et al. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci. Transl. Med., 5, 2013, 196ra98.
55. Costa, C., Ebi, H., Martini, M., Beausoleil, S.A., Faber, A.C., Jakubik, C.T., Huang, A., Wang, Y., Nishtala, M., Hall, B., et al. Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer. Cancer Cell 27 (2015), 97–108.
56. Costa-Mattioli, M., Sonenberg, N., RAPping production of type I interferon in pDCs through mTOR. Nat. Immunol. 9 (2008), 1097–1099.
57. Coutré, S.E., Barrientos, J.C., Brown, J.R., de Vos, S., Furman, R.R., Keating, M.J., Li, D., O'Brien, S.M., Pagel, J.M., Poleski, M.H., et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk. Lymphoma 56 (2015), 2779–2786.
58. Damoulakis, G., Gambardella, L., Rossman, K.L., Lawson, C.D., Anderson, K.E., Fukui, Y., Welch, H.C., Der, C.J., Stephens, L.R., Hawkins, P.T., P-Rex1 directly activates RhoG to regulate GPCR-driven Rac signalling and actin polarity in neutrophils. J. Cell Sci. 127 (2014), 2589–2600.
59. Dang, C.V., MYC on the path to cancer. Cell 149 (2012), 22–35.
60. Deane, J.A., Fruman, D.A., Phosphoinositide 3-kinase: diverse roles in immune cell activation. Annu. Rev. Immunol. 22 (2004), 563–598.
61. Delmore, J.E., Issa, G.C., Lemieux, M.E., Rahl, P.B., Shi, J., Jacobs, H.M., Kastritis, E., Gilpatrick, T., Paranal, R.M., Qi, J., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146 (2011), 904–917.
62. Dengler, H.S., Baracho, G.V., Omori, S.A., Bruckner, S., Arden, K.C., Castrillon, D.H., DePinho, R.A., Rickert, R.C., Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiation. Nat. Immunol. 9 (2008), 1388–1398.
63. Deprez, J., Vertommen, D., Alessi, D.R., Hue, L., Rider, M.H., Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase B and other protein kinases of the insulin signaling cascades. J. Biol. Chem. 272 (1997), 17269–17275.
64. Dibble, C.C., Cantley, L.C., Regulation of mTORC1 by PI3K signaling. Trends Cell Biol. 25 (2015), 545–555.
65. Dickler, M.N., Saura, C., Richards, D.A., Krop, I.E., Cervantes, A., Bedard, P.L., Patel, M.R., Pusztai, L., Oliveira, M., Ware, J.A., et al. A phase II study of the PI3K inhibitor taselisib(GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative(HER2-), hormone receptor-positive (HR+) advanced breast cancer (BC). J. Clin. Oncol., 34, 2016, 520.
66. Dominguez-Sola, D., Kung, J., Holmes, A.B., Wells, V.A., Mo, T., Basso, K., Dalla-Favera, R., The FOXO1 transcription factor instructs the germinal center dark zone program. Immunity 43 (2015), 1064–1074.
67. Donahue, A.C., Fruman, D.A., Distinct signaling mechanisms activate the target of rapamycin in response to different B-cell stimuli. Eur. J. Immunol. 37 (2007), 2923–2936.
68. Dorman, J.B., Albinder, B., Shroyer, T., Kenyon, C., The age-1 and daf-2 genes function in a common pathway to control the lifespan of Caenorhabditis elegans. Genetics 141 (1995), 1399–1406.
69. Dornan, G.L., Siempelkamp, B.D., Jenkins, M.L., Vadas, O., Lucas, C.L., Burke, J.E., Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in PIK3CD and PIK3R1. Proc. Natl. Acad. Sci. USA 114 (2017), 1982–1987.
70. Dowling, R.J., Topisirovic, I., Alain, T., Bidinosti, M., Fonseca, B.D., Petroulakis, E., Wang, X., Larsson, O., Selvaraj, A., Liu, Y., et al. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 328 (2010), 1172–1176.
71. Düvel, K., Yecies, J.L., Menon, S., Raman, P., Lipovsky, A.I., Souza, A.L., Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S., et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 39 (2010), 171–183.
72. Ebner, M., Lučić, I., Leonard, T.A., Yudushkin, I., PI(3,4,5)P3 engagement restricts akt activity to cellular membranes. Mol. Cell 65 (2017), 416–431.e6.
73. Edgar, K.A., Wallin, J.J., Berry, M., Lee, L.B., Prior, W.W., Sampath, D., Friedman, L.S., Belvin, M., Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors. Cancer Res. 70 (2010), 1164–1172.
74. Elkabets, M., Vora, S., Juric, D., Morse, N., Mino-Kenudson, M., Muranen, T., Tao, J., Campos, A.B., Rodon, J., Ibrahim, Y.H., et al. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. Sci. Transl. Med., 5, 2013, 196ra99.
75. Engelman, J.A., Luo, J., Cantley, L.C., The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7 (2006), 606–619.
76. Fabre, S., Carrette, F., Chen, J., Lang, V., Semichon, M., Denoyelle, C., Lazar, V., Cagnard, N., Dubart-Kupperschmitt, A., Mangeney, M., et al. FOXO1 regulates L-selectin and a network of human T cell homing molecules downstream of phosphatidylinositol 3-kinase. J. Immunol. 181 (2008), 2980–2989.
77. Falasca, M., Maffucci, T., Regulation and cellular functions of class II phosphoinositide 3-kinases. Biochem. J. 443 (2012), 587–601.
78. Fan, Q., Aksoy, O., Wong, R.A., Ilkhanizadeh, S., Novotny, C.J., Gustafson, W.C., Truong, A.Y.-Q., Cayanan, G., Simonds, E.F., Haas-Kogan, D., et al. A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma. Cancer Cell 31 (2017), 424–435.
79. Farkona, S., Diamandis, E.P., Blasutig, I.M., Cancer immunotherapy: the beginning of the end of cancer?. BMC Med., 14, 2016, 73.
80. Fazio, N., Buzzoni, R., Baudin, E., Antonuzzo, L., Hubner, R.A., Lahner, H., DE Herder, W.W., Raderer, M., Teulé, A., Capdevila, J., et al. A phase II study of BEZ235 in patients with everolimus-resistant, advanced pancreatic neuroendocrine tumours. Anticancer Res. 36 (2016), 713–719.
81. Feng, D.D., Cai, W., Chen, X., The associations between Parkinson's disease and cancer: the plot thickens. Transl. Neurodegener., 4, 2015, 20.
82. Foukas, L.C., Claret, M., Pearce, W., Okkenhaug, K., Meek, S., Peskett, E., Sancho, S., Smith, A.J., Withers, D.J., Vanhaesebroeck, B., Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441 (2006), 366–370.
83. Foukas, L.C., Bilanges, B., Bettedi, L., Pearce, W., Ali, K., Sancho, S., Withers, D.J., Vanhaesebroeck, B., Long-term p110α PI3K inactivation exerts a beneficial effect on metabolism. EMBO Mol. Med. 5 (2013), 563–571.
84. Franco, J., Witkiewicz, A.K., Knudsen, E.S., CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer. Oncotarget 5 (2014), 6512–6525.
85. Franz, D.N., Belousova, E., Sparagana, S., Bebin, E.M., Frost, M., Kuperman, R., Witt, O., Kohrman, M.H., Flamini, J.R., Wu, J.Y., et al. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncol. 15 (2014), 1513–1520.
86. Friedman, L.S., Edgar, K.A., Song, K., Schmidt, S., Kirkpatrick, D.S., Phu, L., Nannini, M.A., Hong, R., Cheng, E., Crocker, L., et al. Abstract S6-04: The PI3K inhibitor, taselisib, has enhanced potency in PIK3CA mutant models through a unique mechanism of action. Cancer Res, 77, 2017 S6–04 – S6–04.
87. Fritsch, C., Huang, A., Chatenay-Rivauday, C., Schnell, C., Reddy, A., Liu, M., Kauffmann, A., Guthy, D., Erdmann, D., De Pover, A., et al. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol. Cancer Ther. 13 (2014), 1117–1129.
88. Fruman, D.A., Cantley, L.C., Idelalisib–a PI3Kδ inhibitor for B-cell cancers. N. Engl. J. Med. 370 (2014), 1061–1062.
89. Fruman, D.A., Mauvais-Jarvis, F., Pollard, D.A., Yballe, C.M., Brazil, D., Bronson, R.T., Kahn, C.R., Cantley, L.C., Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha. Nat. Genet. 26 (2000), 379–382.
90. Fruman, D.A., Satterthwaite, A.B., Witte, O.N., Xid-like phenotypes: a B cell signalosome takes shape. Immunity 13 (2000), 1–3.
91. Furman, R.R., Sharman, J.P., Coutre, S.E., Cheson, B.D., Pagel, J.M., Hillmen, P., Barrientos, J.C., Zelenetz, A.D., Kipps, T.J., Flinn, I., et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 370 (2014), 997–1007.
92. Gallagher, E.J., Fierz, Y., Vijayakumar, A., Haddad, N., Yakar, S., LeRoith, D., Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia. Oncogene 31 (2012), 3213–3222.
93. Gammon, A., Jasperson, K., Champine, M., Genetic basis of Cowden syndrome and its implications for clinical practice and risk management. Appl. Clin. Genet. 9 (2016), 83–92.
94. García-García, C., Ibrahim, Y.H., Serra, V., Calvo, M.T., Guzmán, M., Grueso, J., Aura, C., Pérez, J., Jessen, K., Liu, Y., et al. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin. Cancer Res. 18 (2012), 2603–2612.
95. Garrett, J.T., Sutton, C.R., Kurupi, R., Bialucha, C.U., Ettenberg, S.A., Collins, S.D., Sheng, Q., Wallweber, J., Defazio-Eli, L., Arteaga, C.L., Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers. Cancer Res. 73 (2013), 6013–6023.
96. Gasser, J.A., Inuzuka, H., Lau, A.W., Wei, W., Beroukhim, R., Toker, A., SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer. Mol. Cell 56 (2014), 595–607.
97. Ghobrial, I.M., Siegel, D.S., Vij, R., Berdeja, J.G., Richardson, P.G., Neuwirth, R., Patel, C.G., Zohren, F., Wolf, J.L., TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia. Am. J. Hematol. 91 (2016), 400–405.
98. González-Billalabeitia, E., Seitzer, N., Song, S.J., Song, M.S., Patnaik, A., Liu, X.-S., Epping, M.T., Papa, A., Hobbs, R.M., Chen, M., et al. Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. Cancer Discov. 4 (2014), 896–904.
99. Gopal, A.K., Kahl, B.S., de Vos, S., Wagner-Johnston, N.D., Schuster, S.J., Jurczak, W.J., Flinn, I.W., Flowers, C.R., Martin, P., Viardot, A., et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N. Engl. J. Med. 370 (2014), 1008–1018.
100. Guichard, S.M., Curwen, J., Bihani, T., D'Cruz, C.M., Yates, J.W.T., Grondine, M., Howard, Z., Davies, B.R., Bigley, G., Klinowska, T., et al. AZD2014, an inhibitor of mTORC1 and mTORC2, is highly effective in ER+ breast cancer when administered using intermittent or continuous schedules. Mol. Cancer Ther. 14 (2015), 2508–2518.
101. Gunderson, A.J., Kaneda, M.M., Tsujikawa, T., Nguyen, A.V., Affara, N.I., Ruffell, B., Gorjestani, S., Liudahl, S.M., Truitt, M., Olson, P., et al. Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer. Cancer Discov. 6 (2016), 270–285.
102. Gupta, A., Anjomani-Virmouni, S., Koundouros, N., Dimitriadi, M., Choo-Wing, R., Valle, A., Zheng, Y., Chiu, Y.-H., Agnihotri, S., Zadeh, G., et al. PARK2 depletion connects energy and oxidative stress to PI3K/Akt activation via PTEN S-nitrosylation. Mol. Cell 65 (2017), 999–1013.e7.
103. Harbst, K., Lauss, M., Cirenajwis, H., Isaksson, K., Rosengren, F., Törngren, T., Kvist, A., Johansson, M.C., Vallon-Christersson, J., Baldetorp, B., et al. Multiregion whole-exome sequencing uncovers the genetic evolution and mutational heterogeneity of early-stage metastatic melanoma. Cancer Res. 76 (2016), 4765–4774.
104. Hawkins, P.T., Stephens, L.R., PI3K signalling in inflammation. Biochim. Biophys. Acta 1851 (2015), 882–897.
105. Hawkins, P.T., Stephens, L.R., Emerging evidence of signalling roles for PI(3,4)P2 in Class I and II PI3K-regulated pathways. Biochem. Soc. Trans. 44 (2016), 307–314.
106. Hay, N., Interplay between FOXO, TOR, and Akt. Biochim. Biophys. Acta 1813 (2011), 1965–1970.
107. Heitman, J., Movva, N.R., Hall, M.N., Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253 (1991), 905–909.
108. De Henau, O., Rausch, M., Winkler, D., Campesato, L.F., Liu, C., Cymerman, D.H., Budhu, S., Ghosh, A., Pink, M., Tchaicha, J., et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature 539 (2016), 443–447.
109. Henske, E.P., McCormack, F.X., Lymphangioleiomyomatosis - a wolf in sheep's clothing. J. Clin. Invest. 122 (2012), 3807–3816.
110. Herman, P.K., Emr, S.D., Characterization of VPS34, a gene required for vacuolar protein sorting and vacuole segregation in Saccharomyces cerevisiae. Mol. Cell. Biol. 10 (1990), 6742–6754.
111. Herman, S.E.M., Niemann, C.U., Farooqui, M., Jones, J., Mustafa, R.Z., Lipsky, A., Saba, N., Martyr, S., Soto, S., Valdez, J., et al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia 28 (2014), 2188–2196.
112. Herrera-Abreu, M.T., Palafox, M., Asghar, U., Rivas, M.A., Cutts, R.J., Garcia-Murillas, I., Pearson, A., Guzman, M., Rodriguez, O., Grueso, J., et al. Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res. 76 (2016), 2301–2313.
113. Hess Michelini, R., Doedens, A.L., Goldrath, A.W., Hedrick, S.M., Differentiation of CD8 memory T cells depends on Foxo1. J. Exp. Med. 210 (2013), 1189–1200.
114. Heurtier, L., Lamrini, H., Chentout, L., Deau, M.-C., Bouafia, A., Rosain, J., Plaza, J.-M., Parisot, M., Dumont, B., Turpin, D., et al. Mutations in the adaptor-binding domain and associated linker region of p110δ cause Activated PI3K-δ Syndrome 1 (APDS1). Haematologica 102 (2017), e278–e281.
115. Hopkins, B.D., Goncalves, M.D., Cantley, L.C., Obesity and cancer mechanisms: cancer metabolism. J. Clin. Oncol. 34 (2016), 4277–4283.
116. Hosford, S.R., Dillon, L.M., Bouley, S.J., Rosati, R., Yang, W., Chen, V.S., Demidenko, E., Morra, R.P., Miller, T.W., Combined inhibition of both p110α and p110β isoforms of phosphatidylinositol 3-kinase is required for sustained therapeutic effect in PTEN-deficient, ER(+) breast cancer. Clin. Cancer Res. 23 (2016), 2795–2805.
117. Houslay, D.M., Anderson, K.E., Chessa, T., Kulkarni, S., Fritsch, R., Downward, J., Backer, J.M., Stephens, L.R., Hawkins, P.T., Coincident signals from GPCRs and receptor tyrosine kinases are uniquely transduced by PI3Kβ in myeloid cells. Sci. Signal., 9, 2016, ra82.
118. Hsu, P., Santner-Nanan, B., Hu, M., Skarratt, K., Lee, C.H., Stormon, M., Wong, M., Fuller, S.J., Nanan, R., IL-10 potentiates differentiation of human induced regulatory T cells via STAT3 and Foxo1. J. Immunol. 195 (2015), 3665–3674.
119. Hsu, P.P., Kang, S.A., Rameseder, J., Zhang, Y., Ottina, K.A., Lim, D., Peterson, T.R., Choi, Y., Gray, N.S., Yaffe, M.B., et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332 (2011), 1317–1322.
120. Hu, H., Juvekar, A., Lyssiotis, C.A., Lien, E.C., Albeck, J.G., Oh, D., Varma, G., Hung, Y.P., Ullas, S., Lauring, J., et al. Phosphoinositide 3-kinase regulates glycolysis through mobilization of aldolase from the actin cytoskeleton. Cell 164 (2016), 433–446.
121. Huang, S., Czech, M.P., The GLUT4 glucose transporter. Cell Metab. 5 (2007), 237–252.
122. Hudson, K., Hancox, U.J., Trigwell, C., McEwen, R., Polanska, U.M., Nikolaou, M., Morentin Gutierrez, P., Avivar-Valderas, A., Delpuech, O., Dudley, P., et al. Intermittent high-dose scheduling of AZD8835, a novel selective inhibitor of PI3Kα and PI3Kδ, demonstrates treatment strategies for PIK3CA-dependent breast cancers. Mol. Cancer Ther. 15 (2016), 877–889.
123. Ibrahim, Y.H., García-García, C., Serra, V., He, L., Torres-Lockhart, K., Prat, A., Anton, P., Cozar, P., Guzmán, M., Grueso, J., et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2 (2012), 1036–1047.
124. Ilagan, E., Manning, B.D., Emerging role of mTOR in the response to cancer therapeutics. Trends Cancer 2 (2016), 241–251.
125. Ilic, N., Utermark, T., Widlund, H.R., Roberts, T.M., PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc. Natl. Acad. Sci. USA 108 (2011), E699–E708.
126. Iyer, G., Hanrahan, A.J., Milowsky, M.I., Al-Ahmadie, H., Scott, S.N., Janakiraman, M., Pirun, M., Sander, C., Socci, N.D., Ostrovnaya, I., et al. Genome sequencing identifies a basis for everolimus sensitivity. Science, 338, 2012, 221.
127. Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S.Y., Huang, Q., Qin, J., Su, B., SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127 (2006), 125–137.
128. Janku, F., Wheler, J.J., Naing, A., Falchook, G.S., Hong, D.S., Stepanek, V.M., Fu, S., Piha-Paul, S.A., Lee, J.J., Luthra, R., et al. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 73 (2013), 276–284.
129. Jansen, V.M., Bhola, N.E., Bauer, J.A., Formisano, L., Lee, K.-M., Hutchinson, K.E., Witkiewicz, A.K., Moore, P.D., Estrada, M.V., Sánchez, V., et al. Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer. Cancer Res. 77 (2017), 2488–2499.
130. Jellusova, J., Rickert, R.C., The PI3K pathway in B cell metabolism. Crit. Rev. Biochem. Mol. Biol. 51 (2016), 359–378.
131. Jellusova, J., Cato, M.H., Apgar, J.R., Ramezani-Rad, P., Leung, C.R., Chen, C., Richardson, A.D., Conner, E.M., Benschop, R.J., Woodgett, J.R., Rickert, R.C., Gsk3 is a metabolic checkpoint regulator in B cells. Nat. Immunol. 18 (2017), 303–312.
132. Johnson, S.C., Rabinovitch, P.S., Kaeberlein, M., mTOR is a key modulator of ageing and age-related disease. Nature 493 (2013), 338–345.
133. Jóźwiak, S., Sadowski, K., Kotulska, K., Schwartz, R.A., Topical use of mammalian target of rapamycin (mTOR) inhibitors in tuberous sclerosis complex: A comprehensive review of the literature. Pediatr. Neurol. 61 (2016), 21–27.
134. Juric, D., Castel, P., Griffith, M., Griffith, O.L., Won, H.H., Ellis, H., Ebbesen, S.H., Ainscough, B.J., Ramu, A., Iyer, G., et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature 518 (2015), 240–244.
135. Juric, D., Krop, I., Ramanathan, R.K., Wilson, T.R., Ware, J.A., Sanabria Bohorquez, S., Savage, H., Sampath, D., Salphati, L., Lin, R., et al. Phase I dose escalation study of taselisib (GDC-0032), an oral PI3K inhibitor, in patients with advanced solid tumors. Cancer Discov. 7 (2017), 704–715.
136. Juric, D., de Bono, J.S., LoRusso, P.M., Nemunaitis, J., Heath, E.I., Kwak, E.L., Macarulla Mercade, T., Geuna, E., de Miguel Luken, M.J., Patel, C., et al. A First-in-human, phase I, dose-escalation study of TAK-117, a selective PI3Kα isoform inhibitor, in patients with advanced solid malignancies. Clin. Cancer Res., 2017, 10.1158/1078-0432.CCR-16-2888 Published online May 10, 2017.
137. Juvekar, A., Burga, L.N., Hu, H., Lunsford, E.P., Ibrahim, Y.H., Balmañà, J., Rajendran, A., Papa, A., Spencer, K., Lyssiotis, C.A., et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov. 2 (2012), 1048–1063.
138. Kaneda, M.M., Messer, K.S., Ralainirina, N., Li, H., Leem, C.J., Gorjestani, S., Woo, G., Nguyen, A.V., Figueiredo, C.C., Foubert, P., et al. PI3Kγ is a molecular switch that controls immune suppression. Nature 539 (2016), 437–442.
139. Kaneda, M.M., Cappello, P., Nguyen, A.V., Ralainirina, N., Hardamon, C.R., Foubert, P., Schmid, M.C., Sun, P., Mose, E., Bouvet, M., et al. Macrophage pi3kγ drives pancreatic ductal adenocarcinoma progression. Cancer Discov. 6 (2016), 870–885.
140. Kerdiles, Y.M., Beisner, D.R., Tinoco, R., Dejean, A.S., Castrillon, D.H., DePinho, R.A., Hedrick, S.M., Foxo1 links homing and survival of naive T cells by regulating L-selectin, CCR7 and interleukin 7 receptor. Nat. Immunol. 10 (2009), 176–184.
141. Kerdiles, Y.M., Stone, E.L., Beisner, D.R., McGargill, M.A., Ch'en, I.L., Stockmann, C., Katayama, C.D., Hedrick, S.M., Foxo transcription factors control regulatory T cell development and function. Immunity 33 (2010), 890–904.
142. Kharas, M.G., Janes, M.R., Scarfone, V.M., Lilly, M.B., Knight, Z.A., Shokat, K.M., Fruman, D.A., Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J. Clin. Invest. 118 (2008), 3038–3050.
143. Krueger, D.A., Wilfong, A.A., Mays, M., Talley, C.M., Agricola, K., Tudor, C., Capal, J., Holland-Bouley, K., Franz, D.N., Long-term treatment of epilepsy with everolimus in tuberous sclerosis. Neurology 87 (2016), 2408–2415.
144. Ku, B.M., Yi, S.Y., Koh, J., Bae, Y.-H., Sun, J.-M., Lee, S.-H., Ahn, J.S., Park, K., Ahn, M.-J., The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. Oncotarget 7 (2016), 14803–14813.
145. Kulkarni, S., Sitaru, C., Jakus, Z., Anderson, K.E., Damoulakis, G., Davidson, K., Hirose, M., Juss, J., Oxley, D., Chessa, T.A., et al. PI3Kβ plays a critical role in neutrophil activation by immune complexes. Sci. Signal., 4, 2011, ra23.
146. Kurebayashi, Y., Nagai, S., Ikejiri, A., Ohtani, M., Ichiyama, K., Baba, Y., Yamada, T., Egami, S., Hoshii, T., Hirao, A., et al. PI3K-Akt-mTORC1-S6K1/2 axis controls Th17 differentiation by regulating Gfi1 expression and nuclear translocation of RORγ. Cell Rep. 1 (2012), 360–373.
147. Kurek, K.C., Luks, V.L., Ayturk, U.M., Alomari, A.I., Fishman, S.J., Spencer, S.A., Mulliken, J.B., Bowen, M.E., Yamamoto, G.L., Kozakewich, H.P.W., Warman, M.L., Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. Am. J. Hum. Genet. 90 (2012), 1108–1115.
148. Kurimchak, A.M., Shelton, C., Duncan, K.E., Johnson, K.J., Brown, J., O'Brien, S., Gabbasov, R., Fink, L.S., Li, Y., Lounsbury, N., et al. Resistance to BET bromodomain inhibitors is mediated by kinome reprogramming in ovarian cancer. Cell Rep. 16 (2016), 1273–1286.
149. Lam, H.C., Nijmeh, J., Henske, E.P., New developments in the genetics and pathogenesis of tumours in tuberous sclerosis complex. J. Pathol. 241 (2017), 219–225.
150. Lampson, B.L., Kasar, S.N., Matos, T.R., Morgan, E.A., Rassenti, L., Davids, M.S., Fisher, D.C., Freedman, A.S., Jacobson, C.A., Armand, P., et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood 128 (2016), 195–203.
151. Lastwika, K.J., Wilson, W. 3rd, Li, Q.K., Norris, J., Xu, H., Ghazarian, S.R., Kitagawa, H., Kawabata, S., Taube, J.M., Yao, S., et al. Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer. Cancer Res. 76 (2016), 227–238.
152. Lawrence, M.S., Stojanov, P., Mermel, C.H., Robinson, J.T., Garraway, L.A., Golub, T.R., Meyerson, M., Gabriel, S.B., Lander, E.S., Getz, G., Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505 (2014), 495–501.
153. Le, X., Antony, R., Razavi, P., Treacy, D.J., Luo, F., Ghandi, M., Castel, P., Scaltriti, M., Baselga, J., Garraway, L.A., Systematic functional characterization of resistance to PI3K inhibition in breast cancer. Cancer Discov. 6 (2016), 1134–1147.
154. Lien, E.C., Lyssiotis, C.A., Cantley, L.C., Metabolic Reprogramming by the PI3K-Akt-mTOR Pathway in Cancer. Recent Results Cancer Res. 207 (2016), 39–72.
155. Lim, S.M., Park, H.S., Kim, S., Kim, S., Ali, S.M., Greenbowe, J.R., Yang, I.S., Kwon, N.-J., Lee, J.L., Ryu, M.-H., et al. Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus. Oncotarget 7 (2016), 10547–10556.
156. Limon, J.J., Fruman, D.A., Akt and mTOR in B cell activation and differentiation. Front. Immunol., 3, 2012, 228.
157. Limon, J.J., So, L., Jellbauer, S., Chiu, H., Corado, J., Sykes, S.M., Raffatellu, M., Fruman, D.A., mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition. Proc. Natl. Acad. Sci. USA 111 (2014), E5076–E5085.
158. Lin, A., Piao, H.-L., Zhuang, L., Sarbassov, D., Ma, L., Gan, B., FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway. Cancer Res. 74 (2014), 1682–1693.
159. Lin, W.H., Adams, W.C., Nish, S.A., Chen, Y.H., Yen, B., Rothman, N.J., Kratchmarov, R., Okada, T., Klein, U., Reiner, S.L., Asymmetric PI3K signaling driving developmental and regenerative cell fate bifurcation. Cell Rep. 13 (2015), 2203–2218.
160. Linke, M., Pham, H.T., Katholnig, K., Schnöller, T., Miller, A., Demel, F., Schütz, B., Rosner, M., Kovacic, B., Sukhbaatar, N., et al. Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression. Nat. Immunol. 18 (2017), 293–302.
161. Liu, H., Radisky, D.C., Yang, D., Xu, R., Radisky, E.S., Bissell, M.J., Bishop, J.M., MYC suppresses cancer metastasis by direct transcriptional silencing of αv and β3 integrin subunits. Nat. Cell Biol. 14 (2012), 567–574.
162. Liu, N., Rowley, B.R., Bull, C.O., Schneider, C., Haegebarth, A., Schatz, C.A., Fracasso, P.R., Wilkie, D.P., Hentemann, M., Wilhelm, S.M., et al. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models. Mol. Cancer Ther. 12 (2013), 2319–2330.
163. Liu, P., Gan, W., Chin, Y.R., Ogura, K., Guo, J., Zhang, J., Wang, B., Blenis, J., Cantley, L.C., Toker, A., et al. PtdIns(3,4,5)P3-dependent activation of the mTORC2 kinase complex. Cancer Discov. 5 (2015), 1194–1209.
164. Loconte, D.C., Grossi, V., Bozzao, C., Forte, G., Bagnulo, R., Stella, A., Lastella, P., Cutrone, M., Benedicenti, F., Susca, F.C., et al. Molecular and functional characterization of three different postzygotic mutations in PIK3CA-related overgrowth spectrum (PROS) patients: Effects on PI3K/AKT/mTOR signaling and sensitivity to PIK3 inhibitors. PLoS ONE, 10, 2015, e0123092.
165. Lord, C.J., Ashworth, A., BRCAness revisited. Nat. Rev. Cancer 16 (2016), 110–120.
166. Loron, M.-C., Grange, S., Guerrot, D., Di Fiore, F., Freguin, C., Hanoy, M., Le Roy, F., Poussard, G., Etienne, I., Legallicier, B., et al. Pneumocystis jirovecii pneumonia in everolimus-treated renal cell carcinoma. J. Clin. Oncol. 33 (2015), e45–e47.
167. LoRusso, P., Shapiro, G., Pandya, S.S., Kwak, E.L., Jones, C., Belvin, M., Musib, L.C., de Crespigny, A., McKenzie, M., Gates, M.R., et al. A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors. J. Clin. Oncol., 30, 2012, 2566.
168. Low, P.C., Manzanero, S., Mohannak, N., Narayana, V.K., Nguyen, T.H., Kvaskoff, D., Brennan, F.H., Ruitenberg, M.J., Gelderblom, M., Magnus, T., et al. PI3Kδ inhibition reduces TNF secretion and neuroinflammation in a mouse cerebral stroke model. Nat. Commun., 5, 2014, 3450.
169. Lucas, C.L., Chandra, A., Nejentsev, S., Condliffe, A.M., Okkenhaug, K., PI3Kδ and primary immunodeficiencies. Nat. Rev. Immunol. 16 (2016), 702–714.
170. Luo, C.T., Liao, W., Dadi, S., Toure, A., Li, M.O., Graded Foxo1 activity in Treg cells differentiates tumour immunity from spontaneous autoimmunity. Nature 529 (2016), 532–536.
171. Luo, J., Field, S.J., Lee, J.Y., Engelman, J.A., Cantley, L.C., The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex. J. Cell Biol. 170 (2005), 455–464.
172. Luo, J., Sobkiw, C.L., Logsdon, N.M., Watt, J.M., Signoretti, S., O'Connell, F., Shin, E., Shim, Y., Pao, L., Neel, B.G., et al. Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase. Proc. Natl. Acad. Sci. USA 102 (2005), 10238–10243.
173. Luo, J., Sobkiw, C.L., Hirshman, M.F., Logsdon, M.N., Li, T.Q., Goodyear, L.J., Cantley, L.C., Loss of class IA PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia. Cell Metab. 3 (2006), 355–366.
174. Ma, C.X., Luo, J., Naughton, M., Ademuyiwa, F., Suresh, R., Griffith, M., Griffith, O.L., Skidmore, Z.L., Spies, N.C., Ramu, A., et al. A phase I trial of BKM120 (Buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor-positive metastatic breast cancer. Clin. Cancer Res. 22 (2016), 1583–1591.
175. Macintyre, A.N., Finlay, D., Preston, G., Sinclair, L.V., Waugh, C.M., Tamas, P., Feijoo, C., Okkenhaug, K., Cantrell, D.A., Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism. Immunity 34 (2011), 224–236.
176. Magnuson, B., Ekim, B., Fingar, D.C., Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem. J. 441 (2012), 1–21.
177. Malka-Mahieu, H., Newman, M., Désaubry, L., Robert, C., Vagner, S., Molecular pathways: The eIF4F translation initiation complex-new opportunities for cancer treatment. Clin. Cancer Res. 23 (2017), 21–25.
178. Mallon, R., Feldberg, L.R., Lucas, J., Chaudhary, I., Dehnhardt, C., Santos, E.D., Chen, Z., dos Santos, O., Ayral-Kaloustian, S., Venkatesan, A., Hollander, I., Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor. Clin. Cancer Res. 17 (2011), 3193–3203.
179. Manning, B.D., Toker, A., AKT/PKB signaling: Navigating the network. Cell 169 (2017), 381–405.
180. Marcotte, R., Sayad, A., Brown, K.R., Sanchez-Garcia, F., Reimand, J., Haider, M., Virtanen, C., Bradner, J.E., Bader, G.D., Mills, G.B., et al. Functional genomic landscape of human breast cancer drivers, vulnerabilities, and resistance. Cell 164 (2016), 293–309.
181. Marshall, N.A., Galvin, K.C., Corcoran, A.M., Boon, L., Higgs, R., Mills, K.H., Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors. Cancer Res. 72 (2012), 581–591.
182. Marwick, J.A., Caramori, G., Casolari, P., Mazzoni, F., Kirkham, P.A., Adcock, I.M., Chung, K.F., Papi, A., A role for phosphoinositol 3-kinase delta in the impairment of glucocorticoid responsiveness in patients with chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 125 (2010), 1146–1153.
183. Matulonis, U.A., Wulf, G.M., Barry, W.T., Birrer, M., Westin, S.N., Farooq, S., Bell-McGuinn, K.M., Obermayer, E., Whalen, C., Spagnoletti, T., et al. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer. Ann. Oncol. 28 (2016), 512–518.
184. Mayer, I.A., Abramson, V.G., Formisano, L., Balko, J.M., Estrada, M.V., Sanders, M.E., Juric, D., Solit, D., Berger, M.F., Won, H.H., et al. A phase Ib study of alpelisib (BYL719), a PI3Kα-specific inhibitor, with letrozole in ER+/HER2- metastatic breast cancer. Clin. Cancer Res. 23 (2017), 26–34.
185. McCormack, F.X., Inoue, Y., Moss, J., Singer, L.G., Strange, C., Nakata, K., Barker, A.F., Chapman, J.T., Brantly, M.L., Stocks, J.M., et al. National Institutes of Health Rare Lung Diseases Consortium, MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N. Engl. J. Med. 364 (2011), 1595–1606.
186. McGranahan, N., Swanton, C., Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168 (2017), 613–628.
187. McGranahan, N., Favero, F., de Bruin, E.C., Birkbak, N.J., Szallasi, Z., Swanton, C., Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci. Transl. Med., 7, 2015, 283ra54.
188. Mertz, J.A., Conery, A.R., Bryant, B.M., Sandy, P., Balasubramanian, S., Mele, D.A., Bergeron, L., Sims, R.J. 3rd, Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl. Acad. Sci. USA 108 (2011), 16669–16674.
189. Michalarea, V., Roda, D., Drew, Y., Carreira, S., O'Carrigan, B.S., Shaw, H., Roux, R., Kumar, S., Ward, S., Parmar, M., et al. Abstract CT010: Phase I trial combining the PARP inhibitor olaparib (Ola) and AKT inhibitor AZD5363 (AZD) in germline (g)BRCA and non-BRCA mutant (m) advanced cancer patients (pts) incorporating noninvasive monitoring of cancer mutations. Cancer Res., 76, 2016, CT010.
190. Miled, N., Yan, Y., Hon, W.-C., Perisic, O., Zvelebil, M., Inbar, Y., Schneidman-Duhovny, D., Wolfson, H.J., Backer, J.M., Williams, R.L., Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317 (2007), 239–242.
191. Miller, A.T., Wilcox, H.M., Lai, Z., Berg, L.J., Signaling through Itk promotes T helper 2 differentiation via negative regulation of T-bet. Immunity 21 (2004), 67–80.
192. Mizrachi, A., Shamay, Y., Shah, J., Brook, S., Soong, J., Rajasekhar, V.K., Humm, J.L., Healey, J.H., Powell, S.N., Baselga, J., et al. Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma. Nat. Commun., 8, 2017, 14292.
193. Moniz, L.S., Surinova, S., Ghazaly, E., Velasco, L.G., Haider, S., Rodríguez-Prados, J.C., Berenjeno, I.M., Chelala, C., Vanhaesebroeck, B., Phosphoproteomic comparison of Pik3ca and Pten signalling identifies the nucleotidase NT5C as a novel AKT substrate. Sci. Rep., 7, 2017, 39985.
194. Morris, J.Z., Tissenbaum, H.A., Ruvkun, G., A phosphatidylinositol-3-OH kinase family member regulating longevity and diapause in Caenorhabditis elegans. Nature 382 (1996), 536–539.
195. Munoz, J., Kurzrock, R., Targeted therapy in rare cancers–adopting the orphans. Nat. Rev. Clin. Oncol. 9 (2012), 631–642.
196. Muranen, T., Selfors, L.M., Worster, D.T., Iwanicki, M.P., Song, L., Morales, F.C., Gao, S., Mills, G.B., Brugge, J.S., Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 21 (2012), 227–239.
197. Nakanishi, Y., Walter, K., Spoerke, J.M., O'Brien, C., Huw, L.Y., Hampton, G.M., Lackner, M.R., Activating mutations in PIK3CB confer resistance to PI3K inhibition and define a novel oncogenic role for p110β. Cancer Res. 76 (2016), 1193–1203.
198. Nashed, B.F., Zhang, T., Al-Alwan, M., Srinivasan, G., Halayko, A.J., Okkenhaug, K., Vanhaesebroeck, B., Hayglass, K.T., Marshall, A.J., Role of the phosphoinositide 3-kinase p110delta in generation of type 2 cytokine responses and allergic airway inflammation. Eur. J. Immunol. 37 (2007), 416–424.
199. Nathan, N., Keppler-Noreuil, K.M., Biesecker, L.G., Moss, J., Darling, T.N., Mosaic disorders of the pi3k/pten/akt/tsc/mtorc1 signaling pathway. Dermatol. Clin. 35 (2017), 51–60.
200. Ni, J., Liu, Q., Xie, S., Carlson, C., Von, T., Vogel, K., Riddle, S., Benes, C., Eck, M., Roberts, T., et al. Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent. Cancer Discov. 2 (2012), 425–433.
201. Nish, S.A., Zens, K.D., Kratchmarov, R., Lin, W.W., Adams, W.C., Chen, Y.H., Yen, B., Rothman, N.J., Bhandoola, A., Xue, H.H., et al. CD4+ T cell effector commitment coupled to self-renewal by asymmetric cell divisions. J. Exp. Med. 214 (2017), 39–47.
202. Okkenhaug, K., Signaling by the phosphoinositide 3-kinase family in immune cells. Annu. Rev. Immunol. 31 (2013), 675–704.
203. Okkenhaug, K., Vanhaesebroeck, B., PI3K in lymphocyte development, differentiation and activation. Nat. Rev. Immunol. 3 (2003), 317–330.
204. Okkenhaug, K., Bilancio, A., Farjot, G., Priddle, H., Sancho, S., Peskett, E., Pearce, W., Meek, S.E., Salpekar, A., Waterfield, M.D., et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 297 (2002), 1031–1034.
205. Okkenhaug, K., Patton, D.T., Bilancio, A., Garçon, F., Rowan, W.C., Vanhaesebroeck, B., The p110delta isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells. J. Immunol. 177 (2006), 5122–5128.
206. Okkenhaug, K., Graupera, M., Vanhaesebroeck, B., Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis, and immunotherapy. Cancer Discov. 6 (2016), 1090–1105.
207. Omori, S.A., Cato, M.H., Anzelon-Mills, A., Puri, K.D., Shapiro-Shelef, M., Calame, K., Rickert, R.C., Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling. Immunity 25 (2006), 545–557.
208. O'Reilly, K.E., Rojo, F., She, Q.-B., Solit, D., Mills, G.B., Smith, D., Lane, H., Hofmann, F., Hicklin, D.J., Ludwig, D.L., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66 (2006), 1500–1508.
209. Osthus, R.C., Shim, H., Kim, S., Li, Q., Reddy, R., Mukherjee, M., Xu, Y., Wonsey, D., Lee, L.A., Dang, C.V., Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J. Biol. Chem. 275 (2000), 21797–21800.
210. Pai, C., Walsh, C.M., Fruman, D.A., Context-specific function of S6K2 in Th cell differentiation. J. Immunol. 197 (2016), 3049–3058.
211. Pan, H., Finkel, T., Key proteins and pathways that regulate lifespan. J. Biol. Chem. 292 (2017), 6452–6460.
212. Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12 (2012), 252–264.
213. Patton, D.T., Garden, O.A., Pearce, W.P., Clough, L.E., Monk, C.R., Leung, E., Rowan, W.C., Sancho, S., Walker, L.S., Vanhaesebroeck, B., Okkenhaug, K., Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells. J. Immunol. 177 (2006), 6598–6602.
214. Peng, W., Chen, J.Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M.T., Xu, C., McKenzie, J.A., Zhang, C., Liang, X., et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 6 (2016), 202–216.
215. Pickrell, A.M., Youle, R.J., The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron 85 (2015), 257–273.
216. + T cell differentiation. J. Clin. Invest. 125 (2015), 2090–2108.
217. Pollizzi, K.N., Sun, I.H., Patel, C.H., Lo, Y.C., Oh, M.H., Waickman, A.T., Tam, A.J., Blosser, R.L., Wen, J., Delgoffe, G.M., Powell, J.D., Asymmetric inheritance of mTORC1 kinase activity during division dictates CD8(+) T cell differentiation. Nat. Immunol. 17 (2016), 704–711.
218. Porstmann, T., Santos, C.R., Griffiths, B., Cully, M., Wu, M., Leevers, S., Griffiths, J.R., Chung, Y.-L., Schulze, A., SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 8 (2008), 224–236.
219. Powles, T., Lackner, M.R., Oudard, S., Escudier, B., Ralph, C., Brown, J.E., Hawkins, R.E., Castellano, D., Rini, B.I., Staehler, M.D., et al. Randomized open-label phase II trial of apitolisib (GDC-0980), a novel inhibitor of the PI3K/mammalian target of rapamycin pathway, versus everolimus in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 34 (2016), 1660–1668.
220. Prokopenko, I., Poon, W., Mägi, R., Prasad B, R., Salehi, S.A., Almgren, P., Osmark, P., Bouatia-Naji, N., Wierup, N., Fall, T., et al. A central role for GRB10 in regulation of islet function in man. PLoS Genet., 10, 2014, e1004235.
221. Ragon, B.K., Kantarjian, H., Jabbour, E., Ravandi, F., Cortes, J., Borthakur, G., DeBose, L., Zeng, Z., Schneider, H., Pemmaraju, N., et al. Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. Am. J. Hematol. 92 (2017), 7–11.
222. Raïch-Regué, D., Fabian, K.P., Watson, A.R., Fecek, R.J., Storkus, W.J., Thomson, A.W., Intratumoral delivery of mTORC2-deficient dendritic cells inhibits B16 melanoma growth by promoting CD8(+) effector T cell responses. OncoImmunology, 5, 2016, e1146841.
223. Ramadani, F., Bolland, D.J., Garcon, F., Emery, J.L., Vanhaesebroeck, B., Corcoran, A.E., Okkenhaug, K., The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development. Sci. Signal., 3, 2010, ra60.
224. Rathmell, J.C., Fox, C.J., Plas, D.R., Hammerman, P.S., Cinalli, R.M., Thompson, C.B., Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol. Cell. Biol. 23 (2003), 7315–7328.
225. Rehman, F.L., Lord, C.J., Ashworth, A., The promise of combining inhibition of PI3K and PARP as cancer therapy. Cancer Discov. 2 (2012), 982–984.
226. Reiner, S.L., Adams, W.C., Lymphocyte fate specification as a deterministic but highly plastic process. Nat. Rev. Immunol. 14 (2014), 699–704.
227. Roberts, D.J., Tan-Sah, V.P., Smith, J.M., Miyamoto, S., Akt phosphorylates HK-II at Thr-473 and increases mitochondrial HK-II association to protect cardiomyocytes. J. Biol. Chem. 288 (2013), 23798–23806.
228. Rodrik-Outmezguine, V.S., Okaniwa, M., Yao, Z., Novotny, C.J., McWhirter, C., Banaji, A., Won, H., Wong, W., Berger, M., de Stanchina, E., et al. Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature 534 (2016), 272–276.
229. Rolf, J., Bell, S.E., Kovesdi, D., Janas, M.L., Soond, D.R., Webb, L.M., Santinelli, S., Saunders, T., Hebeis, B., Killeen, N., et al. Phosphoinositide 3-kinase activity in T cells regulates the magnitude of the germinal center reaction. J. Immunol. 185 (2010), 4042–4052.
230. Ross, S.H., Rollings, C., Anderson, K.E., Hawkins, P.T., Stephens, L.R., Cantrell, D.A., Phosphoproteomic Analyses of Interleukin 2 Signaling Reveal Integrated JAK Kinase-Dependent and -Independent Networks in CD8(+) T Cells. Immunity 45 (2016), 685–700.
231. Rückle, T., Schwarz, M.K., Rommel, C., PI3Kgamma inhibition: towards an ‘aspirin of the 21st century’?. Nat. Rev. Drug Discov. 5 (2006), 903–918.
232. Saito, K., Tolias, K.F., Saci, A., Koon, H.B., Humphries, L.A., Scharenberg, A., Rawlings, D.J., Kinet, J.P., Carpenter, C.L., BTK regulates PtdIns-4,5-P2 synthesis: importance for calcium signaling and PI3K activity. Immunity 19 (2003), 669–678.
233. Salmond, R.J., Emery, J., Okkenhaug, K., Zamoyska, R., MAPK, phosphatidylinositol 3-kinase, and mammalian target of rapamycin pathways converge at the level of ribosomal protein S6 phosphorylation to control metabolic signaling in CD8 T cells. J. Immunol. 183 (2009), 7388–7397.
234. Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S.M., Riggins, G.J., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science, 304, 2004, 554.
235. Sander, S., Chu, V.T., Yasuda, T., Franklin, A., Graf, R., Calado, D.P., Li, S., Imami, K., Selbach, M., Di Virgilio, M., et al. PI3 kinase and FOXO1 transcription factor activity differentially control B cells in the germinal center light and dark zones. Immunity 43 (2015), 1075–1086.
236. Sarbassov, D.D., Guertin, D.A., Ali, S.M., Sabatini, D.M., Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005), 1098–1101.
237. 1) in the TORC1 pathway is essential for the differentiation of Th17 Cells, but not Th1, Th2, or Treg cells in mice. Eur. J. Immunol. 46 (2016), 212–222.
238. Saxton, R.A., Sabatini, D.M., mTOR signaling in growth, metabolism, and disease. Cell 168 (2017), 960–976.
239. Schmid, M.C., Avraamides, C.J., Dippold, H.C., Franco, I., Foubert, P., Ellies, L.G., Acevedo, L.M., Manglicmot, J.R., Song, X., Wrasidlo, W., et al. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression. Cancer Cell 19 (2011), 715–727.
240. Schmit, F., Utermark, T., Zhang, S., Wang, Q., Von, T., Roberts, T.M., Zhao, J.J., PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context. Proc. Natl. Acad. Sci. USA 111 (2014), 6395–6400.
241. Schwartz, S., Wongvipat, J., Trigwell, C.B., Hancox, U., Carver, B.S., Rodrik-Outmezguine, V., Will, M., Yellen, P., de Stanchina, E., Baselga, J., et al. Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ. Cancer Cell 27 (2015), 109–122.
242. Selman, C., Tullet, J.M.A., Wieser, D., Irvine, E., Lingard, S.J., Choudhury, A.I., Claret, M., Al-Qassab, H., Carmignac, D., Ramadani, F., et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 326 (2009), 140–144.
243. Sherr, C.J., Bartek, J., Cell cycle-targeted cancer therapies. Annual Review of Cancer Biology 1 (2017), 41–57.
244. Shimizu, T., Tolcher, A.W., Papadopoulos, K.P., Beeram, M., Rasco, D.W., Smith, L.S., Gunn, S., Smetzer, L., Mays, T.A., Kaiser, B., et al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin. Cancer Res. 18 (2012), 2316–2325.
245. Shojaee, S., Chan, L.N., Buchner, M., Cazzaniga, V., Cosgun, K.N., Geng, H., Qiu, Y.H., von Minden, M.D., Ernst, T., Hochhaus, A., et al. PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nat. Med. 22 (2016), 379–387.
246. Sinclair, L.V., Rolf, J., Emslie, E., Shi, Y.B., Taylor, P.M., Cantrell, D.A., Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation. Nat. Immunol. 14 (2013), 500–508.
247. So, L., Lee, J., Palafox, M., Mallya, S., Woxland, C.G., Arguello, M., Truitt, M.L., Sonenberg, N., Ruggero, D., Fruman, D.A., The 4E-BP-eIF4E axis promotes rapamycin-sensitive growth and proliferation in lymphocytes. Sci. Signal., 9, 2016, ra57.
248. Soond, D.R., Bjørgo, E., Moltu, K., Dale, V.Q., Patton, D.T., Torgersen, K.M., Galleway, F., Twomey, B., Clark, J., Gaston, J.S., et al. PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans. Blood 115 (2010), 2203–2213.
249. Soond, D.R., Slack, E.C., Garden, O.A., Patton, D.T., Okkenhaug, K., Does the PI3K pathway promote or antagonize regulatory T cell development and function?. Front. Immunol., 3, 2012, 244.
250. Stamatkin, C., Ratermann, K.L., Overley, C.W., Black, E.P., Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms. Cancer Biol. Ther. 16 (2015), 1341–1352.
251. Stone, E.L., Pepper, M., Katayama, C.D., Kerdiles, Y.M., Lai, C.Y., Emslie, E., Lin, Y.C., Yang, E., Goldrath, A.W., Li, M.O., et al. ICOS coreceptor signaling inactivates the transcription factor FOXO1 to promote Tfh cell differentiation. Immunity 42 (2015), 239–251.
252. Stratikopoulos, E.E., Dendy, M., Szabolcs, M., Khaykin, A.J., Lefebvre, C., Zhou, M.M., Parsons, R., Kinase and BET inhibitors together clamp inhibition of PI3K signaling and overcome resistance to therapy. Cancer Cell 27 (2015), 837–851.
253. Sugimoto, Y., Whitman, M., Cantley, L.C., Erikson, R.L., Evidence that the Rous sarcoma virus transforming gene product phosphorylates phosphatidylinositol and diacylglycerol. Proc. Natl. Acad. Sci. USA 81 (1984), 2117–2121.
254. Sun, M., Hillmann, P., Hofmann, B.T., Hart, J.R., Vogt, P.K., Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. Proc. Natl. Acad. Sci. USA 107 (2010), 15547–15552.
255. Sun, Y., Peng, I., Webster, J.D., Suto, E., Lesch, J., Wu, X., Senger, K., Francis, G., Barrett, K., Collier, J.L., et al. Inhibition of the kinase ITK in a mouse model of asthma reduces cell death and fails to inhibit the inflammatory response. Sci. Signal., 8, 2015, ra122.
256. Switon, K., Kotulska, K., Janusz-Kaminska, A., Zmorzynska, J., Jaworski, J., Tuberous sclerosis complex: From molecular biology to novel therapeutic approaches. IUBMB Life 68 (2016), 955–962.
257. Tain, L.S., Mortiboys, H., Tao, R.N., Ziviani, E., Bandmann, O., Whitworth, A.J., Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat. Neurosci. 12 (2009), 1129–1135.
258. Tamura, K., Hashimoto, J., Tanabe, Y., Kodaira, M., Yonemori, K., Seto, T., Hirai, F., Arita, S., Toyokawa, G., Chen, L., et al. Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors. Cancer Chemother. Pharmacol. 77 (2016), 787–795.
259. Taniguchi, C.M., Kondo, T., Sajan, M., Luo, J., Bronson, R., Asano, T., Farese, R., Cantley, L.C., Kahn, C.R., Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta. Cell Metab. 3 (2006), 343–353.
260. Terauchi, Y., Tsuji, Y., Satoh, S., Minoura, H., Murakami, K., Okuno, A., Inukai, K., Asano, T., Kaburagi, Y., Ueki, K., et al. Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Nat. Genet. 21 (1999), 230–235.
261. Thien, A., Prentzell, M.T., Holzwarth, B., Kläsener, K., Kuper, I., Boehlke, C., Sonntag, A.G., Ruf, S., Maerz, L., Nitschke, R., et al. TSC1 activates TGF-β-Smad2/3 signaling in growth arrest and epithelial-to-mesenchymal transition. Dev. Cell 32 (2015), 617–630.
262. Thomas, G.V., Tran, C., Mellinghoff, I.K., Welsbie, D.S., Chan, E., Fueger, B., Czernin, J., Sawyers, C.L., Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med. 12 (2006), 122–127.
263. Thorpe, L.M., Yuzugullu, H., Zhao, J.J., PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat. Rev. Cancer 15 (2015), 7–24.
264. Toska, E., Osmanbeyoglu, H.U., Castel, P., Chan, C., Hendrickson, R.C., Elkabets, M., Dickler, M.N., Scaltriti, M., Leslie, C.S., Armstrong, S.A., Baselga, J., PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science 355 (2017), 1324–1330.
265. Uchi, R., Takahashi, Y., Niida, A., Shimamura, T., Hirata, H., Sugimachi, K., Sawada, G., Iwaya, T., Kurashige, J., Shinden, Y., et al. Integrated multiregional analysis proposing a new model of colorectal cancer evolution. PLoS Genet., 12, 2016, e1005778.
266. Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., Bilanges, B., The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol. 11 (2010), 329–341.
267. Venkataraman, S., Alimova, I., Balakrishnan, I., Harris, P., Birks, D.K., Griesinger, A., Amani, V., Cristiano, B., Remke, M., Taylor, M.D., et al. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget 5 (2014), 2355–2371.
268. Verbist, K.C., Guy, C.S., Milasta, S., Liedmann, S., Kamiński, M.M., Wang, R., Green, D.R., Metabolic maintenance of cell asymmetry following division in activated T lymphocytes. Nature 532 (2016), 389–393.
269. Vora, S.R., Juric, D., Kim, N., Mino-Kenudson, M., Huynh, T., Costa, C., Lockerman, E.L., Pollack, S.F., Liu, M., Li, X., et al. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell 26 (2014), 136–149.
270. Voss, M.H., Hakimi, A.A., Pham, C.G., Brannon, A.R., Chen, Y.-B., Cunha, L.F., Akin, O., Liu, H., Takeda, S., Scott, S.N., et al. Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clin. Cancer Res. 20 (2014), 1955–1964.
271. Wagle, N., Grabiner, B.C., Van Allen, E.M., Amin-Mansour, A., Taylor-Weiner, A., Rosenberg, M., Gray, N., Barletta, J.A., Guo, Y., Swanson, S.J., et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N. Engl. J. Med. 371 (2014), 1426–1433.
272. Waickman, A.T., Powell, J.D., mTOR, metabolism, and the regulation of T-cell differentiation and function. Immunol. Rev. 249 (2012), 43–58.
273. Waldhart, A.N., Dykstra, H., Peck, A.S., Boguslawski, E.A., Madaj, Z.B., Wen, J., Veldkamp, K., Hollowell, M., Zheng, B., Cantley, L.C., et al. Phosphorylation of TXNIP by AKT mediates acute influx of glucose in response to insulin. Cell Rep. 19 (2017), 2005–2013.
274. Wang, D., Wang, M., Jiang, N., Zhang, Y., Bian, X., Wang, X., Roberts, T.M., Zhao, J.J., Liu, P., Cheng, H., Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer. Oncotarget 7 (2016), 13153–13166.
275. Wei, W., Shin, Y.S., Xue, M., Matsutani, T., Masui, K., Yang, H., Ikegami, S., Gu, Y., Herrmann, K., Johnson, D., et al. Single-cell phosphoproteomics resolves adaptive signaling dynamics and informs targeted combination therapy in glioblastoma. Cancer Cell 29 (2016), 563–573.
276. Weichhart, T., Hengstschläger, M., Linke, M., Regulation of innate immune cell function by mTOR. Nat. Rev. Immunol. 15 (2015), 599–614.
277. Weigelt, B., Warne, P.H., Lambros, M.B., Reis-Filho, J.S., Downward, J., PI3K pathway dependencies in endometrioid endometrial cancer cell lines. Clin. Cancer Res. 19 (2013), 3533–3544.
278. Welch, H.C.E., Coadwell, W.J., Ellson, C.D., Ferguson, G.J., Andrews, S.R., Erdjument-Bromage, H., Tempst, P., Hawkins, P.T., Stephens, L.R., P-Rex1, a PtdIns(3,4,5)P3- and Gbetagamma-regulated guanine-nucleotide exchange factor for Rac. Cell 108 (2002), 809–821.
279. Whitman, M., Kaplan, D.R., Schaffhausen, B., Cantley, L., Roberts, T.M., Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature 315 (1985), 239–242.
280. Whitman, M., Downes, C.P., Keeler, M., Keller, T., Cantley, L., Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature 332 (1988), 644–646.
281. Wieman, H.L., Wofford, J.A., Rathmell, J.C., Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol. Biol. Cell 18 (2007), 1437–1446.
282. Wlodarski, P., Kasprzycka, M., Liu, X., Marzec, M., Robertson, E.S., Slupianek, A., Wasik, M.A., Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum. Cancer Res. 65 (2005), 7800–7808.
283. Worby, C.A., Dixon, J.E., PTEN. Annu. Rev. Biochem. 83 (2014), 641–669.
284. Wu, J.J., Liu, J., Chen, E.B., Wang, J.J., Cao, L., Narayan, N., Fergusson, M.M., Rovira, I.I., Allen, M., Springer, D.A., et al. Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression. Cell Rep. 4 (2013), 913–920.
285. Yates, D.H., mTOR treatment in lymphangioleiomyomatosis: the role of everolimus. Expert Rev. Respir. Med. 10 (2016), 249–260.
286. Yates, L.R., Gerstung, M., Knappskog, S., Desmedt, C., Gundem, G., Van Loo, P., Aas, T., Alexandrov, L.B., Larsimont, D., Davies, H., et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat. Med. 21 (2015), 751–759.
287. Yu, Y., Yoon, S.O., Poulogiannis, G., Yang, Q., Ma, X.M., Villén, J., Kubica, N., Hoffman, G.R., Cantley, L.C., Gygi, S.P., Blenis, J., Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332 (2011), 1322–1326.
288. Yuasa, T., Uchiyama, K., Ogura, Y., Kimura, M., Teshigawara, K., Hosaka, T., Tanaka, Y., Obata, T., Sano, H., Kishi, K., Ebina, Y., The Rab GTPase-activating protein AS160 as a common regulator of insulin- and Galphaq-mediated intracellular GLUT4 vesicle distribution. Endocr. J. 56 (2009), 345–359.
289. Zelenetz, A.D., Barrientos, J.C., Brown, J.R., Coiffier, B., Delgado, J., Egyed, M., Ghia, P., Illés, Á., Jurczak, W., Marlton, P., et al. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 18 (2017), 297–311.
290. Zhang, K.J., Husami, A., Marsh, R., Jordan, M.B., Identification of a phosphoinositide 3-kinase (PI-3K) p 110 δ (PIK3CD) deficient individual. J. Clin. Immunol. 33 (2013), 673–674.
291. Zuber, J., Shi, J., Wang, E., Rappaport, A.R., Herrmann, H., Sison, E.A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478 (2011), 524–528.